Feld JJ, et al. - This trial entailed the elucidation of the clinical management of ribavirin dosing in hepatitis C virus-infected patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin. Multivariate stepwise logistic regression models assessed predictors associated with ribavirin dose adjustments and with developing anaemia. It was observed that 6.5% cases modified ribavirin dose due to haemoglobin declines, of which 99% achieved sustained virological response at 12 weeks post-treatment. The inference drawn was that ribavirin dose reductions were infrequent, occurred early in treatment, and did not affect the sustained virological response at 12 weeks post-treatment. Monitoring was recommended for subjects with low baseline haemoglobin for on-treatment anaemia.